Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038511595> ?p ?o ?g. }
- W3038511595 endingPage "113396" @default.
- W3038511595 startingPage "113396" @default.
- W3038511595 abstract "Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expansion of a polyglutamine repeat in the huntingtin (HTT) protein. Aberrant activation of caspase-6 and cleavage of mutant HTT generating the toxic N-terminal 586 HTT fragment are important steps in the pathogenesis of HD. Similarly, alterations in the insulin-like growth factor 1 (IGF-1) signaling pathway have been implicated in the disease as a result of decreased plasma IGF-1 levels in HD patients. In addition, two recent studies have demonstrated therapeutic benefit of IGF-1 treatment in mouse models of HD. Since IGF-1 promotes pro-survival pathways, we examined the relationship between IGF-1 signaling and aberrant caspase-6 activation in HD. Using immortalized mouse striatal cells expressing wild-type (STHdhQ7) or mutant HTT (STHdhQ111), we show that reduced levels of IGF-1 are associated with enhanced activation of caspase-6, increased cell death, and mutant HTT cleavage in a cellular stress paradigm. We demonstrate that IGF-1 supplementation reverses these effects and lowers the level of the toxic 586 HTT fragment. In addition, transcriptional analysis in the R6/2 HD transgenic mouse model demonstrated that the IGF-1 signaling system is dysregulated at multiple levels in several tissues including liver, muscle, and brain. Among these changes, we found increased expression of IGF-1 binding protein 3 (IGFBP-3), which may further reduce the bioavailability of IGF-1 as a consequence of increased IGF-1 binding. Our findings thus suggest that the therapeutic benefit of IGF-1 supplementation in HD may be significantly improved if other defects in the IGF-1 signaling pathway are corrected concurrently." @default.
- W3038511595 created "2020-07-10" @default.
- W3038511595 creator A5006854193 @default.
- W3038511595 creator A5010528585 @default.
- W3038511595 creator A5024671081 @default.
- W3038511595 creator A5047722409 @default.
- W3038511595 creator A5054652807 @default.
- W3038511595 creator A5054708177 @default.
- W3038511595 creator A5061436028 @default.
- W3038511595 creator A5067562719 @default.
- W3038511595 creator A5082965726 @default.
- W3038511595 date "2020-10-01" @default.
- W3038511595 modified "2023-09-29" @default.
- W3038511595 title "Compromised IGF signaling causes caspase-6 activation in Huntington disease" @default.
- W3038511595 cites W1525687971 @default.
- W3038511595 cites W1745634660 @default.
- W3038511595 cites W1964312788 @default.
- W3038511595 cites W1965732243 @default.
- W3038511595 cites W1968449538 @default.
- W3038511595 cites W1968469766 @default.
- W3038511595 cites W1974897920 @default.
- W3038511595 cites W1982328539 @default.
- W3038511595 cites W1985050276 @default.
- W3038511595 cites W1988969017 @default.
- W3038511595 cites W1992876087 @default.
- W3038511595 cites W1993130330 @default.
- W3038511595 cites W1993418561 @default.
- W3038511595 cites W1995138363 @default.
- W3038511595 cites W1995856801 @default.
- W3038511595 cites W2001824068 @default.
- W3038511595 cites W2011369409 @default.
- W3038511595 cites W2012271704 @default.
- W3038511595 cites W2015041659 @default.
- W3038511595 cites W2017949036 @default.
- W3038511595 cites W2025605031 @default.
- W3038511595 cites W2027260046 @default.
- W3038511595 cites W2030377763 @default.
- W3038511595 cites W2034891521 @default.
- W3038511595 cites W2042879634 @default.
- W3038511595 cites W2049334581 @default.
- W3038511595 cites W2050390944 @default.
- W3038511595 cites W2052847951 @default.
- W3038511595 cites W2055277064 @default.
- W3038511595 cites W2061916566 @default.
- W3038511595 cites W2062682951 @default.
- W3038511595 cites W2066330966 @default.
- W3038511595 cites W2067443877 @default.
- W3038511595 cites W2068663841 @default.
- W3038511595 cites W2081861269 @default.
- W3038511595 cites W2089577924 @default.
- W3038511595 cites W2090634025 @default.
- W3038511595 cites W2093663819 @default.
- W3038511595 cites W2093730240 @default.
- W3038511595 cites W2096944314 @default.
- W3038511595 cites W2098217384 @default.
- W3038511595 cites W2100397515 @default.
- W3038511595 cites W2108468164 @default.
- W3038511595 cites W2113011235 @default.
- W3038511595 cites W2113784200 @default.
- W3038511595 cites W2113964087 @default.
- W3038511595 cites W2116520593 @default.
- W3038511595 cites W2118531470 @default.
- W3038511595 cites W2119481903 @default.
- W3038511595 cites W2128517811 @default.
- W3038511595 cites W2129630363 @default.
- W3038511595 cites W2130012866 @default.
- W3038511595 cites W2133417537 @default.
- W3038511595 cites W2135732941 @default.
- W3038511595 cites W2135783352 @default.
- W3038511595 cites W2140639536 @default.
- W3038511595 cites W2143027879 @default.
- W3038511595 cites W2143929320 @default.
- W3038511595 cites W2146103593 @default.
- W3038511595 cites W2146933101 @default.
- W3038511595 cites W2147848270 @default.
- W3038511595 cites W2151840082 @default.
- W3038511595 cites W2156243335 @default.
- W3038511595 cites W2157419789 @default.
- W3038511595 cites W2158162884 @default.
- W3038511595 cites W2159050691 @default.
- W3038511595 cites W2170182827 @default.
- W3038511595 cites W2257890299 @default.
- W3038511595 cites W2317698610 @default.
- W3038511595 cites W2327244512 @default.
- W3038511595 cites W2558246874 @default.
- W3038511595 cites W2754579889 @default.
- W3038511595 cites W2769102984 @default.
- W3038511595 cites W2770565967 @default.
- W3038511595 cites W2780490426 @default.
- W3038511595 cites W2794273483 @default.
- W3038511595 cites W2797389850 @default.
- W3038511595 cites W2810108266 @default.
- W3038511595 cites W2909611686 @default.
- W3038511595 cites W2937250781 @default.
- W3038511595 cites W2963250813 @default.
- W3038511595 cites W4211110682 @default.
- W3038511595 cites W4235071471 @default.
- W3038511595 doi "https://doi.org/10.1016/j.expneurol.2020.113396" @default.